These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
264 related articles for article (PubMed ID: 15551031)
1. [MRT of the liver. Clinical significance of nonspecific and liver-specific MRT contrast agents]. Ba-Ssalamah A; Happel B; Kettenbach J; Dirisamer A; Wrba F; Längle F; Schima W Radiologe; 2004 Dec; 44(12):1170-84. PubMed ID: 15551031 [TBL] [Abstract][Full Text] [Related]
2. Mangafodipir trisodium (MnDPDP)-enhanced magnetic resonance imaging of the liver and pancreas. Wang C Acta Radiol Suppl; 1998; 415():1-31. PubMed ID: 9571956 [TBL] [Abstract][Full Text] [Related]
3. [Current status of MRI diagnostics with liver-specific contrast agents. Gd-EOB-DTPA and Gd-BOPTA]. Stroszczynski C; Gaffke G; Gnauck M; Streitparth F; Wieners G; Lopez-Häninnen E Radiologe; 2004 Dec; 44(12):1185-91. PubMed ID: 15549226 [TBL] [Abstract][Full Text] [Related]
4. Contrast agents for MR imaging of the liver. Low RN J Magn Reson Imaging; 1997; 7(1):56-67. PubMed ID: 9039594 [TBL] [Abstract][Full Text] [Related]
5. The role of hepatocyte-specific contrast agents in hepatobiliary magnetic resonance imaging. Burke C; Alexander Grant L; Goh V; Griffin N Semin Ultrasound CT MR; 2013 Feb; 34(1):44-53. PubMed ID: 23395317 [TBL] [Abstract][Full Text] [Related]
6. Hepatobiliary-specific MR contrast agents: role in imaging the liver and biliary tree. Seale MK; Catalano OA; Saini S; Hahn PF; Sahani DV Radiographics; 2009 Oct; 29(6):1725-48. PubMed ID: 19959518 [TBL] [Abstract][Full Text] [Related]
7. Hepatobiliary contrast agents for contrast-enhanced MRI of the liver: properties, clinical development and applications. Reimer P; Schneider G; Schima W Eur Radiol; 2004 Apr; 14(4):559-78. PubMed ID: 14986050 [TBL] [Abstract][Full Text] [Related]
8. [Comparison of biphasic spiral CT and MnDPDP-enhanced MRI in the detection and characterization of liver lesions]. Grimm J; Müller-Hülsbeck S; Blume J; Biederer J; Heller M Rofo; 2001 Mar; 173(3):266-72. PubMed ID: 11293872 [TBL] [Abstract][Full Text] [Related]
9. Detection and characterization of focal hepatic lesions: mangafodipir vs. superparamagnetic iron oxide-enhanced magnetic resonance imaging. Kim MJ; Kim JH; Lim JS; Oh YT; Chung JJ; Choi JS; Lee WJ; Kim KW J Magn Reson Imaging; 2004 Oct; 20(4):612-21. PubMed ID: 15390224 [TBL] [Abstract][Full Text] [Related]
10. [Magnetic resonance imaging of the liver: what kind of contrast agents?]. De Gaspari A; De Cobelli F; Del Maschio A Radiol Med; 2001 Sep; 102(3):109-21. PubMed ID: 11677451 [TBL] [Abstract][Full Text] [Related]
11. Sequential use of gadolinium chelate and mangafodipir trisodium for the assessment of focal liver lesions: initial observations. Martin DR; Semelka RC; Chung JJ; Balci NC; Wilber K Magn Reson Imaging; 2000 Oct; 18(8):955-63. PubMed ID: 11121698 [TBL] [Abstract][Full Text] [Related]
12. Contrast-enhanced MR imaging of the liver. Runge VM; Pels Rijcken TH; Davidoff A; Wells JW; Stark DD J Magn Reson Imaging; 1994; 4(3):281-9. PubMed ID: 8061423 [TBL] [Abstract][Full Text] [Related]
13. Atypical focal nodular hyperplasia of the liver: imaging features of nonspecific and liver-specific MR contrast agents. Ba-Ssalamah A; Schima W; Schmook MT; Linnau KF; Schibany N; Helbich T; Reimer P; Laengle F; Wrba F; Kurtaran A; Ryan M; Mann FA AJR Am J Roentgenol; 2002 Dec; 179(6):1447-56. PubMed ID: 12438034 [TBL] [Abstract][Full Text] [Related]
14. Detection and characterization of focal liver lesions: a Japanese phase III, multicenter comparison between gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced computed tomography predominantly in patients with hepatocellular carcinoma and chronic liver disease. Ichikawa T; Saito K; Yoshioka N; Tanimoto A; Gokan T; Takehara Y; Kamura T; Gabata T; Murakami T; Ito K; Hirohashi S; Nishie A; Saito Y; Onaya H; Kuwatsuru R; Morimoto A; Ueda K; Kurauchi M; Breuer J Invest Radiol; 2010 Mar; 45(3):133-41. PubMed ID: 20098330 [TBL] [Abstract][Full Text] [Related]
15. Mangafodipir trisodium-enhanced MRI for the detection and characterization of focal hepatic lesions: is delayed imaging useful? Chung JJ; Kim MJ; Kim KW J Magn Reson Imaging; 2006 May; 23(5):706-11. PubMed ID: 16565954 [TBL] [Abstract][Full Text] [Related]
16. Imaging liver metastases: review and update. Kanematsu M; Kondo H; Goshima S; Kato H; Tsuge U; Hirose Y; Kim MJ; Moriyama N Eur J Radiol; 2006 May; 58(2):217-28. PubMed ID: 16406434 [TBL] [Abstract][Full Text] [Related]
17. Comparison of gadolinium chelates with manganese-DPDP for liver lesion detection and characterization: preliminary results. Kettritz U; Schlund JF; Wilbur K; Eisenberg LB; Semelka RC Magn Reson Imaging; 1996; 14(10):1185-90. PubMed ID: 9065909 [TBL] [Abstract][Full Text] [Related]
18. Characterization of liver lesions with mangafodipir trisodium-enhanced MR imaging: multicenter study comparing MR and dual-phase spiral CT. Oudkerk M; Torres CG; Song B; König M; Grimm J; Fernandez-Cuadrado J; Op de Beeck B; Marquardt M; van Dijk P; de Groot JC Radiology; 2002 May; 223(2):517-24. PubMed ID: 11997562 [TBL] [Abstract][Full Text] [Related]
19. [The clinical value of Mn-DPDP: a new paramagnetic hepatobiliary contrast medium for magnetic resonance tomography of the liver]. Vogl TJ; Hamm B; Schnell B; Eibl-Eibesfeldt B; Steiner S; Lissner J Rofo; 1991 Dec; 155(6):568-74. PubMed ID: 1764599 [TBL] [Abstract][Full Text] [Related]